Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer

Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world’s leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals. At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women. Earlier results from the study found that adding Kisqali to Femara improved progression-free survival — the amount of time the women lived without the cancer growing. These new results found that the combination of Kisqali and Femara also improved overall survival — the length of time women lived whether the cancer grew or not. Listen to the episode to hear Dr. Hortobagyi explain: the goals of the MONALEESA-2 study why the overall survival difference of more than 1 year is so important whether the improvement in overall survival is likely to be the same no matter which aromatase inhibitor is used what the results mean for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive HER2-negative breast cancer

There are no comments yet.

Please log in to write the first comment.